What type of study is this?

September 27, 2025Therapeutic Advances in Medical OncologyOpen Access

S-1 plus oxaliplatin versus modified FOLFIRINOX for advanced pancreatic adenocarcinoma after gemcitabine plus nab-paclitaxel failure

View Full Paper

Ask AI

Bookmark

Modified FOLFIRINOX significantly enhances progression-free and overall survival in advanced pancreatic cancer compared to SOX.
The disease control rate for mFFX was significantly higher at 68.8%, versus 40.0% with SOX, indicating better treatment efficacy.
Patients receiving mFFX experienced greater instances of severe adverse events, particularly neutropenia and diarrhea, raising safety concerns.
Molecular analysis identified alterations like ARID1A and NTRK2, but these did not influence the choice of chemotherapy regimen.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Retrospective cohort explored efficacy and safety of oxaliplatin plus S-1 versus modified FOLFIRINOX, highlighting significant outcomes in advanced PDAC patients.

Cite This Study

Tang et al. (2025) studied this question.

synapsesocial.com/papers/68d7b3e9eebfec0fc5236d62 https://doi.org/10.1177/17588359251378698

View Full Paper

Ask AI

Bookmark

Implication

Retrospective cohort explored efficacy and safety of oxaliplatin plus S-1 versus modified FOLFIRINOX, highlighting significant outcomes in advanced PDAC patients.

S-1 plus oxaliplatin versus modified FOLFIRINOX for advanced pancreatic adenocarcinoma after gemcitabine plus nab-paclitaxel failure

Key Points

Discussion

Implication

Cite This Study

S-1 plus oxaliplatin versus modified FOLFIRINOX for advanced pancreatic adenocarcinoma after gemcitabine plus nab-paclitaxel failure

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider